Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Intervalo de ano de publicação
1.
Microb Pathog ; 123: 153-161, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30003946

RESUMO

This study was conducted to investigate annexin A1 (ANXA1) functions in human placental explants infected with Toxoplasma gondii (T. gondii). We examined the first and third trimester placental explants infected with T. gondii (n = 7 placentas/group) to identify the number and location of parasites, ANXA1 protein, potential involvement of formyl peptide receptors (FPR1 and FPR2), and COX-2 expressions by immunohistochemistry. Treatments with Ac2-26 mimetic peptide of ANXA1 were performed to verify the parasitism rate (ß-galactosidase assay), prostaglandin E2 levels (ELISA assay), and ANXA1, FPR1 and COX-2 expression in third trimester placentas. Placental explants of third trimester expressed less ANXA1 and were more permissive to T. gondii infection than first trimester placentas that expressed more ANXA1. Ac2-26 treatment increases endogenous ANXA1 and decreases parasitism rate, COX-2, and prostaglandin E2 levels. Altogether, these data provide further insight into the anti-parasitic and anti-inflammatory effects of ANXA1 in placentas infected with T. gondii.


Assuntos
Anexina A1/farmacologia , Antiparasitários/farmacologia , Placenta/efeitos dos fármacos , Toxoplasma/efeitos dos fármacos , Toxoplasma/patogenicidade , Toxoplasmose/tratamento farmacológico , Anti-Inflamatórios/farmacologia , Estudos Transversais , Ciclo-Oxigenase 2/metabolismo , Dinoprostona/metabolismo , Feminino , Humanos , Inflamação/tratamento farmacológico , Peptídeos/farmacologia , Placenta/patologia , Placenta/fisiopatologia , Gravidez , Terceiro Trimestre da Gravidez , Receptores de Formil Peptídeo/metabolismo , Receptores de Lipoxinas/metabolismo , Toxoplasmose/patologia , beta-Galactosidase/análise
2.
Cells ; 10(11)2021 11 15.
Artigo em Inglês | MEDLINE | ID: mdl-34831393

RESUMO

Uveitis is one of the main causes of blindness worldwide, and therapeutic alternatives are worthy of study. We investigated the effects of piperlongumine (PL) and/or annexin A1 (AnxA1) mimetic peptide Ac2-26 on endotoxin-induced uveitis (EIU). Rats were inoculated with lipopolysaccharide (LPS) and intraperitoneally treated with Ac2-26 (200 µg), PL (200 and 400 µg), or Ac2-26 + PL after 15 min. Then, 24 h after LPS inoculation, leukocytes in aqueous humor, mononuclear cells, AnxA1, formyl peptide receptor (fpr)1, fpr2, and cyclooxygenase (COX)-2 were evaluated in the ocular tissues, along with inflammatory mediators in the blood and macerated supernatant. Decreased leukocyte influx, levels of inflammatory mediators, and COX-2 expression confirmed the anti-inflammatory actions of the peptide and pointed to the protective effects of PL at higher dosage. However, when PL and Ac2-26 were administered in combination, the inflammatory potential was lost. AnxA1 expression was elevated among groups treated with PL or Ac2-26 + PL but reduced after treatment with Ac2-26. Fpr2 expression was increased only in untreated EIU and Ac2-26 groups. The interaction between Ac2-26 and PL negatively affected the anti-inflammatory action of Ac2-26 or PL. We emphasize that the anti-inflammatory effects of PL can be used as a therapeutic strategy to protect against uveitis.


Assuntos
Anexina A1/uso terapêutico , Anti-Inflamatórios/uso terapêutico , Dioxolanos/uso terapêutico , Peptídeos/uso terapêutico , Uveíte/induzido quimicamente , Uveíte/tratamento farmacológico , Animais , Anexina A1/administração & dosagem , Anexina A1/farmacologia , Anti-Inflamatórios/farmacologia , Cílios/enzimologia , Cílios/patologia , Ciclo-Oxigenase 2/metabolismo , Dioxolanos/administração & dosagem , Dioxolanos/farmacologia , Endotoxinas , Olho/efeitos dos fármacos , Olho/patologia , Mediadores da Inflamação/metabolismo , Masculino , Modelos Biológicos , Monócitos/efeitos dos fármacos , Neutrófilos/efeitos dos fármacos , Peptídeos/administração & dosagem , Peptídeos/farmacologia , Ratos Wistar , Receptores de Lipoxinas/metabolismo , Uveíte/sangue , Uveíte/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA